

## Annual SHOT Report 2017 – Supplementary Information

### Chapter 17: Transfusion-Transmitted Infections (TTI)

The table below is an excerpt from the full Table 17.3 which can be viewed in the main report.

Case reports with further details of the 7 bacterial and 13 viral transfusion-transmitted infection incidents from 2008 to 2017 have been prepared by the NHSBT/PHE Epidemiology Unit, and are described in the following pages.

#### Number of confirmed TTI incidents by year of transfusion in the UK reported to SHOT between 2008 and 2017

Year of transfusion*	Number of incidents (recipients) by infection											Implicated component				
	Bacteria	HAV	HBV	HCV	HEV	HIV	HTLV I	Parvovirus (B19)	Malaria	vCJD/prion	Total	RBC	Pooled platelet	Apheresis platelet	FFP	Cryo
2008	4 (6)	0	0	0	0	0	0	0	0	0	4 (6)	0	2	4	0	0
2009	2 (3)	0	0	0	0	0	0	0	0	0	2 (3)	1	0	2	0	0
2010	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2011	0	0	1 (2)	0	1 (2)	0	0	0	0	0	2 (4)	2	0	0	2	0
2012	0	0	1 (1)	0	1 (1)	0	0	1 (1)	0	0	3 (3)	2	0	0	1	0
2013	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2014	0	0	0	0	2 (3)	0	0	0	0	0	2 (3)	1	0	0	1	0
2015	1 (1)	0	0	0	4 (5)	0	0	0	0	0	5 (6)	0	3	1	1	1
2016	0	0	0	0	1 (1)	0	0	0	0	0	1 (1)	1	0	0	0	0
2017	0	1 (1)	0	0	0	0	0	0	0	0	1 (1)	0	0	1	0	0

\*No screening was in place for HEV or parvovirus B19 at the time of the documented transmissions

**Bacterial Case 1: *Klebsiella pneumoniae***

<b>Infection</b>	<i>Klebsiella pneumoniae</i>
<b>Year of Transfusion</b>	2008
<b>SHOT report</b>	SHOT report 2008
<b>Component</b>	Platelets-apheresis
<b>Component Age</b>	3 day (pack 1) & 4 day (pack 2)
<b>No. recipients</b>	2
<b>Morbidity</b>	Death
<b>Source</b>	The source of the organism was most likely the donor gut, transferred to the venepuncture site and from there to the donated component. Alternatively this may have been due to a transient bacteraemia in the donor.
<b>Reason TTI occurred</b>	It is recognised that the donor arm cleansing procedure is not 100% effective. If no illness reported and no visual signs of contamination in pack no reason not to issue and use the components of the donation.
<b>Index case</b>	A donation of apheresis platelets was split to produce 2 platelet doses. Pack 1 transfused into neurosurgery patient (head injury) with pre-existing ischaemic bowel, liver disease and sepsis. Pack 2 given to patient with AML with chemotherapy-related pancytopenia.
<b>Diagnosis</b>	The neurosurgery patient died 11 hours post transfusion thought to be due to sepsis from the ischaemic bowel. Transfusion reaction was not suspected at this point and pack 1 was not retained but patient blood cultures were taken prior to death. Five minutes into the transfusion the AML patient became acutely unwell, requiring admission to ITU before cardiac arrest and death. The remains of the transfused pack 2 were cultured at the hospital before being returned to the Blood Service.
<b>Investigation</b>	Blood cultures from both patients prior to death yielded <i>Klebsiella pneumoniae</i> , as did cultures of the unit transfused to the patient with AML, and all 3 isolates were found to be of a single strain. The case was concluded as a proven incident of bacterial contamination of two platelet units with <i>K. pneumoniae</i> .

**Bacterial Case 2: *Streptococcus dysgalactiae* (Group G Streptococcus)**

<b>Infection</b>	<i>Streptococcus dysgalactiae</i> (Group G Streptococcus)
<b>Year of Transfusion</b>	2008
<b>SHOT report</b>	SHOT report 2008
<b>Component</b>	Platelets-apheresis
<b>Component Age</b>	4 day (pack 1) & 5 day (pack 2)
<b>No. recipients</b>	2
<b>Morbidity</b>	Major morbidity
<b>Source</b>	The apheresis donor denied any recent illness or change in bowel habit, but GGS was identified from their stool sample. The likely but unproven chain of transmission was from donor gut to venepuncture site via the donor's fingers, and from there to the donated component. Alternatively this may have been due to a transient bacteraemia in the donor.
<b>Reason TTI occurred</b>	It is recognised that the donor arm cleansing procedure is not 100% effective. If no illness reported and no visual signs of contamination in pack no reason not to issue and use the components of the donation.
<b>Index case</b>	A unit of apheresis platelets was split to produce 2 platelet doses. Pack 1 was transfused to a teenager with acute lymphoblastic leukaemia (ALL). Pack 2 was transfused to a patient in their 50s with acute myeloid leukaemia (AML).
<b>Diagnosis</b>	Recipient of pack 1 (ALL) reacted with allergy-like symptoms. Recipient of pack 2 developed chills, nausea and a feeling of impending doom.
<b>Investigation</b>	The remains of both units were returned to the blood services for investigation, with a delay in the return of pack 1 due to the initial diagnosis of an allergic reaction. Blood cultures from both patients yielded Lancefield Group G streptococcus (GGS), as did cultures of both platelet units carried out at the blood services. GGS are known as both commensals and pathogens in animals and humans. All 5 isolates (from both patients, both packs and the donor) were sent to a national reference laboratory for typing, and were found to be of the same strain.

**Bacterial Case 3: Lancefield Group G Streptococcus**

<b>Infection</b>	Lancefield Group G Streptococcus
<b>Year of Transfusion</b>	2008
<b>SHOT report</b>	SHOT report 2008
<b>Component</b>	Platelets-pooled
<b>Component Age</b>	4 day
<b>No. recipients</b>	1
<b>Morbidity</b>	Major morbidity
<b>Source</b>	Platelet donor who did not report any illness at or around the time of donation either unrecognised or asymptomatic.
<b>Reason TTI occurred</b>	It is recognised that the donor arm cleansing procedure is not 100% effective. If no illness reported and no visual signs of contamination in pack no reason not to issue and use the components of the donation.
<b>Index case</b>	A patient in their 50s with severe aplastic anaemia received 1 unit of pooled platelets.
<b>Diagnosis</b>	Within 5 minutes of starting the infusion the patient developed urticaria and pain along the access vein. Antihistamine was given and the transfusion was continued. One hour later the patient became pyrexial and hypotensive, requiring admission to the ITU.
<b>Investigation</b>	Patient blood cultures revealed Lancefield Group G streptococcus (GGS), as did cultures of the remains of the platelet pool. Associated units (4 red cells, 1 FFP) were recalled but cultures were all negative. The donors contributing to the platelet pool were recalled; GGS was identified in stool samples of 3 of the 4 donors. Typing confirmed that 1 of these isolates represented the same strain as that from both the patient blood cultures and the platelet unit.

**Bacterial Case 4: *Staphylococcus epidermidis***

<b>Infection</b>	<i>Staphylococcus epidermidis</i>
<b>Year of Transfusion</b>	2008
<b>SHOT report</b>	SHOT report 2008
<b>Component</b>	Platelets-pooled
<b>Component Age</b>	6 day
<b>No. recipients</b>	1
<b>Morbidity</b>	Major morbidity
<b>Source</b>	Contamination of the platelet unit by skin flora from the donor venepuncture site was probably responsible for the patient's reaction. <i>S. epidermidis</i> is a common skin commensal.
<b>Reason TTI occurred</b>	It is recognised that the donor arm cleansing procedure is not 100% effective. Informal quality audits carried out by the blood services during 2008 suggested that the procedure could be improved, and an extensive staff re-training exercise was undertaken.
<b>Index case</b>	An elderly patient was transfused with a unit of pooled platelets for thrombocytopenia.
<b>Diagnosis</b>	During the transfusion the patient developed chills, rigors, back pain and hypotension, and the transfusion was stopped.
<b>Investigation</b>	<p><i>Staphylococcus epidermidis</i> isolated from patient blood cultures and from remains of the platelet pack. Four associated red cell units and 1 unit of FFP were negative on culture.</p> <p><i>S. epidermidis</i> was identified from venepuncture site samples from 2/4 of the donors contributing to the platelet pack, from pre-cleaning swabs only. 1 strain was identical to that in platelet pack. The blood culture from the patient was not available for further investigation so it was not possible to determine if all 3 isolates (from patient, donor and pack) were identical.</p>

**Bacterial Case 5: *Pseudomonas koreensis***

<b>Infection</b>	<i>Pseudomonas koreensis</i>
<b>Year of Transfusion</b>	2009
<b>SHOT report</b>	SHOT report 2009
<b>Component</b>	Red cells
<b>Component Age</b>	19 day
<b>No. recipients</b>	1
<b>Morbidity</b>	Death
<b>Source</b>	Unclear: <i>P. koreensis</i> is associated with cold temperatures. Contamination may have occurred within a cold storage room or processing area at blood service or hospital. Skin carriage of <i>P. koreensis</i> is rare. Donor swabs taken from arms were negative. Donor unlikely to have been the source. Despite extensive environmental sampling of processing and cold storage areas at hospital and blood services, source of the contamination could not be identified. Red cell pack was pressure tested but no holes or defects revealed so unclear how the bacteria may have entered the pack.
<b>Reason TTI occurred</b>	Possible environmental contamination in this incident led to an extensive review of cold room cleaning protocols within processing and issues areas.
<b>Index case</b>	Three units of red cells were transfused into an elderly patient receiving palliative care for cancer of the rectum and liver cirrhosis.
<b>Diagnosis</b>	Approximately 2 hours into transfusion of the third unit the patient became unwell with hypotension, fever (39.6°C), abdominal pain and vomiting; the patient died later the same day.
<b>Investigation</b>	<i>Pseudomonas koreensis</i> was cultured from the remains of the red cell unit at the microbiology laboratories of both the hospital and the blood service, and also from the patient blood cultures. All 3 isolates were found to be indistinguishable on molecular typing.

**Bacterial Case 6: *Streptococcus pneumoniae***

<b>Infection</b>	<i>Streptococcus pneumoniae</i>
<b>Year of Transfusion</b>	2009
<b>SHOT report</b>	SHOT report 2009
<b>Component</b>	Platelets-apheresis
<b>Component Age</b>	5day (adult), 3day (baby)
<b>No. recipients</b>	2
<b>Morbidity</b>	Major morbidity
<b>Source</b>	Organism may have originated from the throat of the donor or donor carer and been transferred from there to the venepuncture site by fingers or a cough/sneeze or from an underlying asymptomatic bacteraemia in the donor. Approximately 4–8% of adults carry <i>S. pneumoniae</i> .
<b>Reason TTI occurred</b>	It is recognised that the donor arm cleansing procedure is not 100% effective. If no illness reported and no visual signs of contamination in pack no reason not to issue and use the components of the donation.
<b>Index case</b>	An un-issued, expired unit of apheresis platelets was referred for microbiological testing after routine quality monitoring found pack to have low pH and abnormal colouration. <i>Streptococcus pneumoniae</i> was isolated from the unit.
<b>Diagnosis</b>	Retrospective investigations revealed that both patients had experienced transfusion reactions (including a fever of 39.8°C in the adult patient and 40.5°C in the baby), but these were thought at the time to have been related to the patients' underlying conditions.
<b>Investigation</b>	Four associated units had been transfused into 2 patients with acute myeloid leukaemia (AML)– 1 to an adult and 3 to a baby. All transfused packs were discarded but a blood sample from the adult patient yielded <i>S. pneumoniae</i> . The neonatal patient blood cultures were negative, but on antibiotics at time of transfusion. The isolate from both the contaminated index pack and the adult patient were indistinguishable. Donor nose and throat swabs were negative; however, <i>S. pneumoniae</i> is known to be difficult to culture from swabs.

**Bacterial Case 7: *Staphylococcus aureus***

<b>Infection</b>	<i>Staphylococcus aureus</i>
<b>Year of Transfusion</b>	2015
<b>SHOT report</b>	SHOT report 2015
<b>Component</b>	Platelets-pooled
<b>Component Age</b>	6day
<b>No. recipients</b>	1
<b>Morbidity</b>	Major morbidity
<b>Source</b>	Donor found to carry <i>Staphylococcus aureus</i> , no current or past history of eczema or other skin conditions
<b>Reason TTI occurred</b>	It is recognised that the donor arm cleansing procedure is not 100% effective. There is a small residual risk that bacteria may not be detected during bacterial screening.
<b>Index case</b>	A female neutropenic patient in her 70's with Acute Myeloid Leukaemia was transfused with a six day old pooled platelet unit
<b>Diagnosis</b>	Fifteen minutes into the transfusion, the patient became agitated and experienced symptoms of rigors, tachycardia and pyrexia. The patient's temperature spiked at 38.7°C and continued to rise overnight reaching 40°C.
<b>Investigation</b>	<i>Staphylococcus</i> was initially reported in patient blood cultures. This was later confirmed by the hospital microbiology laboratory to be <i>S. aureus</i> . The same strain of <i>Staphylococcus aureus</i> was isolated from cultures from the almost empty pack of the transfused unit and skin swabs from one of the donors whose donation was included in the pool, this was also confirmed by molecular typing.

**Viral Case 1: Hepatitis E**

<b>Infection</b>	Hepatitis E virus HEV
<b>Year of transfusion</b>	2011
<b>SHOT report year</b>	SHOT Report 2012
<b>Component</b>	FFP / Red cells
<b>No. recipients</b>	2
<b>Morbidity</b>	Major morbidity (Death in index case unrelated to HEV infection)
<b>Source</b>	Repeat male donor, 20-30 year age group.
<b>Possible risk factor</b>	Not reported any illness pre- or post-donation.
<b>Reason TTI occurred</b>	HEV screening currently not required. Illness not reported in donor. Therefore nothing to suggest components from donation should not have been issued.
<b>Index case</b>	Adult recipient of stem cell transplant with associated transfusion support over the Autumn of 2011.
<b>Diagnosis</b>	Recipient developed abnormal LFTs in May 2012. Testing of stored samples established that the recipient had been HEV negative in December 2011 but HEV RNA positive in February 2012.
<b>Investigation</b>	34 donations investigated. Two donors confirmed HEV RNA positive at time of donation: Donor A virus sequence data matched recipient. Recipient received FFP from this donation. Donor B virus had divergent sequence. Unfortunately, the recipient died in Autumn 2012 from causes unrelated to the HEV infection. The 2nd recipient of the same donation (red cells) was HEV RNA negative, but positive for HEV IgG and IgM, a year after transfusion, consistent with previous HEV infection. Donor had cleared the infection and seroconverted when tested six months later.

**Viral Case 2: Hepatitis B**

<b>Infection</b>	Hepatitis B virus (HBV)
<b>Year of transfusion</b>	2011
<b>SHOT report year</b>	SHOT Report 2012
<b>Component</b>	Red cells / FFP
<b>No. recipients</b>	2
<b>Morbidity</b>	Major morbidity
<b>Source</b>	White-British male donor, 30-40 year age group.
<b>Possible risk factor</b>	The only possible reported donor risk was participation in contact sports. Asymptomatic and unaware of his HBV infection.
<b>Reason TTI occurred</b>	A donor with no reported deferrable risks donating with an early HBV infection undetectable by the screening tests in place at the time. Although HBV DNA is not a mandatory blood donation screening test it is included in the Triplex NAT screening test currently used on all donations. It was concluded that the level of HBV DNA was too low to be detected in the pooled NAT screening test.
<b>Index case</b>	A recipient of multiple transfusions during emergency cardiac surgery in August 2011.
<b>Diagnosis</b>	Diagnosed with acute HBV after jaundice and a high ALT test result prompted HBV testing in December 2011. The recipient was shown to be anti-HBc negative on an archived sample from December 2008. The recipient gradually cleared HBV infection over the following months.
<b>Investigation</b>	Fifteen of 16 donors cleared. One donor whose FFP had been transfused to the recipient had evidence of exposure and immunity to HBV (anti-HBc positive/anti-HBs >100 mIU/ml) on a donation 4 months after the implicated index donation. The index donation had been HBsAg screen negative (individual sample testing) and HBV NAT negative in testing of pooled samples. Retrospective individual sample testing of the archived sample of the index donation detected HBV DNA in one of two PCR tests used in the reference laboratory. Retrospective testing of 3 archived donation samples given before July 2011 showed no evidence of exposure to HBV. Lookback into the fate of the associated red cell component from the July index donation revealed chronic asymptomatic HBV infection (HBsAg and HBeAg positive) in the elderly female immunosuppressed recipient. The recipient of red cells from the subsequent donation, at which time the donor had immunity to HBV, was HBV negative.

## Viral Case 3: Hepatitis B

<b>Infection</b>	Hepatitis B virus (HBV)
<b>Year of transfusion</b>	2012
<b>SHOT report year</b>	SHOT Report 2013
<b>Component</b>	Red cells
<b>No. recipients</b>	1
<b>Morbidity</b>	Major morbidity
<b>Source</b>	Repeat female donor , 20-30 year age group.
<b>Possible risk factor</b>	Tattooing reported but not recent ie not requiring deferral or additional testing for anti-HBc. Both donor and recipient of non-UK, European heritage.
<b>Reason TTI occurred</b>	<b>This is a case of probable transmission.</b> A donor with no reported deferrable risks donating with an HBsAg negative infection undetectable by the screening tests in place at the time. Although HBV DNA is not a mandatory blood donation screening test it is included in the Triplex NAT screening test currently used on all donations. The level of HBV DNA was too low to be detected in the pooled NAT screening test.
<b>Index case</b>	An elderly recipient on immunosuppressive therapy received 7 units of red cells in summer 2012, during surgery for a bowel problem.
<b>Diagnosis</b>	Mildly abnormal LFTs in April 2013 prompted HBV testing: recipient HBsAg positive, low level anti-HBc IgM reactive, HBeAg positive, avidity results inconclusive. Virus, genotype A2. A patient sample in June 2013 suggested HBeAg-positive chronic hepatitis B infection.
<b>Investigation</b>	Seven donors investigated. Six negative for evidence of HBV. One HBV DNA reactive on the index archive sample, tested retrospectively by individual sample testing having tested negative by routine pooled Triplex NAT screening at the time of donation. The donor was anti-HBc positive on a subsequent sample. An archive sample from 2011 was anti-HBc positive / HBV DNA negative. A donor follow-up sample was anti-HBs positive / HBV DNA positive. These test results could reflect a resolving HBV infection or reactivation of an occult chronic HBV infection. Recipient had lived in UK all her life. Viral genotyping revealed an HBV virus currently circulating in England, unlikely to have been acquired through vertical transmission. Genotyping of donor virus could not be undertaken due to insufficient HBV DNA in the samples, therefore absolute proof of transmission lacking,

**Viral Case 4: Hepatitis E**

<b>Infection</b>	Hepatitis E virus (HEV)
<b>Year of transfusion</b>	2012
<b>SHOT report year</b>	SHOT Report 2013
<b>Component</b>	FFP
<b>No. recipients</b>	1
<b>Morbidity</b>	Major morbidity
<b>Source</b>	Repeat male donor over 60 years old.
<b>Possible risk factor</b>	Not reported any illness pre- or post-donation.
<b>Reason TTI occurred</b>	HEV screening currently not required. Illness not reported in donor. Therefore nothing to suggest components from donation should not have been issued.
<b>Index case</b>	A recipient with multiple medical problems on immunosuppressive therapy received 129 donor exposures during a period of intensive plasma exchange and blood transfusion in May 2012.
<b>Diagnosis</b>	Recipient developed biochemical hepatitis in mid-August 2012, prompting hepatitis virus testing. He became HEV RNA positive in July 2012 (stored samples tested retrospectively) and seroconverted in August 2012 with subsequent clearance of HEV RNA.
<b>Investigation</b>	The vast majority of the 129 donors were cleared on the basis of subsequent negative serology and all tested index samples were RNA negative except for one. Sequencing studies identified this donation to be the source of infection in the recipient. Donor was HEV RNA positive, anti-HEV negative at the time of the index donation and had cleared virus and seroconverted by the next donation 5 months later.

**Viral Case 5: Parvovirus B19**

<b>Infection</b>	Parvovirus B19
<b>Year of transfusion</b>	2012
<b>SHOT report year</b>	SHOT Report 2012
<b>Component</b>	Red cells
<b>No. recipients</b>	1
<b>Morbidity</b>	Major morbidity
<b>Source</b>	Repeat donor, 20-30 year age group.
<b>Possible risk factor</b>	Not reported any illness pre- or post-donation
<b>Reason TTI occurred</b>	Parvovirus screening not currently required. Illness not reported in donor. Therefore nothing to suggest components from donation should not have been issued.
<b>Index case</b>	A child given a red cell transfusion for sickle cell anaemia in September 2012.
<b>Diagnosis</b>	A temperature of 41°C and lymphopenia 48 hours later. Parvovirus B19 DNA and IgG and IgM antibodies detected approximately 2 weeks post transfusion.
<b>Investigation</b>	The implicated donation was found to be parvovirus B19 DNA positive, IgM negative and IgG equivocal. A subsequent sample from the donor was positive for DNA, IgM and IgG. Both recipient and donor shared the same B19 genotype, although it was a very common form.

**Viral Case 6: Hepatitis E**

<b>Infection</b>	Hepatitis E virus (HEV)
<b>Year of transfusion</b>	2014
<b>SHOT report year</b>	SHOT Report 2014
<b>Component</b>	FFP / Red cells
<b>No. recipients</b>	2
<b>Morbidity</b>	Major morbidity (index case), minor in associated case
<b>Source</b>	Repeat male donor, >55 years
<b>Possible risk factor</b>	Donor was asymptomatic- no illness before or after donation.
<b>Reason TTI occurred</b>	HEV screening not required. No clinical illness in donor. Therefore nothing to suggest components from donation should not have been issued.
<b>Index case</b>	Male recipient in his 70s with multiple chronic medical problems including alcohol-related liver cirrhosis. Received red cells, platelets and FFP totalling 17 donor exposures in September 2014 for lower gastrointestinal bleeding secondary to diverticulitis.
<b>Diagnosis</b>	Discharged from hospital following transfusion but subsequently readmitted with hepatic encephalopathy. Investigation included testing for viral hepatitis markers, with results consistent with acute hepatitis E infection.
<b>Investigation</b>	Testing of 17 donation archive samples identified an HEV RNA positive donation without detectable antibodies. Index recipient received FFP from this donation. A further donor blood sample confirmed clearance of the virus and seroconversion. The recipient liver symptoms and enzyme function had improved by February 2015. The associated red cells were transfused in October 2014 and the recipient had shown no symptoms of HEV infection. A blood sample in February 2015 had test results consistent with a resolving HEV infection. The recipient had received chemotherapy and radiotherapy one year previously, probably accounting for the delayed clearance of the HEV infection, which was nevertheless expected to resolve over the following months.

**Viral Case 7: Hepatitis E**

<b>Infection</b>	Hepatitis E virus (HEV)
<b>Year of transfusion</b>	2014
<b>SHOT report year</b>	SHOT Report 2015
<b>Component</b>	FFP
<b>No. recipients</b>	1
<b>Morbidity</b>	Minor
<b>Source</b>	A repeat male donor > 65
<b>Possible risk factor</b>	Donors were asymptomatic- no illness before or after donation.
<b>Reason TTI occurred</b>	HEV screening not required. No clinical illness in donor. Therefore nothing to suggest components from donation should not have been issued.
<b>Index case</b>	A male liver transplant recipient received 32 blood products during surgery.
<b>Diagnosis</b>	He was found to be significantly viraemic 68 days post-transplant (October 2012) whereas he was negative when assessed in June 2012.
<b>Investigation</b>	An investigation was carried out and it was identified that he had received 5 apheresis platelets, 14 fresh frozen plasma, 9 red blood cell concentrates, 1 platelet pool (4 donors) and 1 cryoprecipitate (5 donors) in August 2012. Two platelets transfused in 2011, prior to CH being reported as HEV positive, were excluded from this investigation. Thirty-seven blood donor exposures were identified. Archive samples from all 37 donations were retrieved and tested for antibodies to HEV (IgG and IgM) and HEV RNA. One donor (FFP) showed evidence of active HEV infection (HEV IgM & HEV RNA positive; HEV IgG negative) at the time of donation. Sequence analysis showed that the sequence in the HEV RNA positive donor was a highly conserved match with the transplant patient sample.

**Viral Case 8: Hepatitis E**

<b>Infection</b>	Hepatitis E virus (HEV)
<b>Year of transfusion</b>	2015
<b>SHOT report year</b>	SHOT Report 2015
<b>Component</b>	Pooled platelets
<b>No. recipients</b>	2
<b>Morbidity</b>	Patient deceased, due to underlying condition, however HEV may have contributed to patients death
<b>Source</b>	Repeat male donor > 25; repeat male donor > 60
<b>Possible risk factor</b>	Donors were asymptomatic- no illness before or after donation.
<b>Reason TTI occurred</b>	HEV screening not required. No clinical illness in donor. Therefore nothing to suggest components from donation should not have been issued.
<b>Index case</b>	A male patient in his 50's (vegetarian) with multifocal CNS (central nervous system) lymphoma diagnosed in December 2014, underwent autologous stem cell transplant for reversible bone marrow failure and had extensive transfusion support including multiple pooled platelets from June 2015.
<b>Diagnosis</b>	HEV testing was carried out in view of persistent transaminitis. The patient eventually died with decompensated liver failure.
<b>Investigation</b>	There were thirty-three donor exposures based on donations transfused in the 12 weeks prior to the first positive result. Two donations by two donors (one pooled platelet transfused on 2 <sup>nd</sup> June 2015 and one apheresis platelet transfused on 21 <sup>st</sup> May 2015) were found through retesting archive samples to have been HEV RNA positive. Due to the changing nature of the virus in the recipient it is not possible to say with certainty whether one or both donations were responsible for the hepatitis E infection, however the apheresis platelet donation had a high viral load and resulted in transmission to the recipient who received the other platelet pack.

**Viral Case 9: Hepatitis E**

<b>Infection</b>	Hepatitis E virus (HEV)
<b>Year of transfusion</b>	2015
<b>SHOT report year</b>	SHOT Report 2015
<b>Component</b>	Platelets / cryoprecipitates
<b>No. recipients</b>	1
<b>Morbidity</b>	Major morbidity
<b>Source</b>	Repeat male donor >75 years
<b>Possible risk factor</b>	Donors were asymptomatic- no illness before or after donation.
<b>Reason TTI occurred</b>	HEV screening not required. No clinical illness in donor. Therefore nothing to suggest components from donation should not have been issued.
<b>Index case</b>	A male patient in his 40's with non-Hodgkin's lymphoma received 2 units of platelets and 2 units of cryoprecipitate in July 2015 (18 donor exposures).
<b>Diagnosis</b>	In October 2015 (80 days post transfusion), he was admitted in hospital for jaundice, nausea and abdominal discomfort. He was HAV, HBV and HCV negative, however he was HEV IgG (low) and IgM (high) positive.
<b>Investigation</b>	Records of all donors were examined. None of the donors had reported any illness at the time of donation or subsequently. Archive samples from the eighteen index donations were tested for HEV RNA, of which one donation which was included in one of the cryoprecipitate doses was HEV RNA positive.

**Viral Case 10: Hepatitis E**

<b>Infection</b>	Hepatitis E virus (HEV)
<b>Year of transfusion</b>	2016
<b>SHOT report year</b>	SHOT Report 2016
<b>Component</b>	Red cells
<b>No. recipients</b>	1
<b>Morbidity</b>	Major morbidity
<b>Source</b>	Repeat male donor >40 years
<b>Possible risk factor</b>	Donors were asymptomatic- no illness before or after donation.
<b>Reason TTI occurred</b>	HEV screening was not required. No clinical illness in donor, therefore nothing to suggest components from donation should not have been issued.
<b>Index case</b>	A male patient in his 70's with aplastic anaemia received regular blood transfusions of two units of red cells every month.
<b>Diagnosis</b>	The patient was noted to have abnormal LFT's when tested on 24 <sup>th</sup> February 2016. Sample dated 2 <sup>nd</sup> March 2016 was reported anti-HEV IgM and IgG positive by PHE Bristol. This sample was referred to PHE Colindale where it was confirmed to be HEV RNA positive with a viral load of 410,000 IU/ml.
<b>Investigation</b>	Records of all donors were examined. None of the donors had reported any illness at the time of donation or subsequently. Archive samples from the ten index donations were tested for HEV RNA, of which one donation was HEV RNA positive, viral load 3574 IU/ml. All donors remain on the donor panel.

**Viral Case 11: Hepatitis E**

<b>Infection</b>	Hepatitis E virus (HEV)
<b>Year of transfusion</b>	2015
<b>SHOT report year</b>	SHOT Report 2017
<b>Component</b>	Pooled platelets
<b>No. recipients</b>	1
<b>Morbidity</b>	Major morbidity
<b>Source</b>	Repeat male donor > 50 years
<b>Possible risk factor</b>	Donor was asymptomatic- no illness before or after donation.
<b>Reason TTI occurred</b>	Pre-dates introduction of routine HEV screening. No clinical illness in donor, therefore nothing to suggest components from donation should not have been issued.
<b>Index case</b>	A male patient in his 60s diagnosed with myelodysplastic syndrome (MDS), proceeding to an allogeneic stem cell transplant, received blood transfusions from late 2014 to mid 2015
<b>Diagnosis</b>	A deterioration in liver function test result in early 2016 led to HEV testing, the patient was HEV IgM positive, IgG not detected
<b>Investigation</b>	Archive samples of all the donations were retrieved and tested for HEV RNA. One donation was identified as HEV RNA positive with a viral load of 2,000,000 IU/mL. The platelet and plasma from this donation was used in preparation of a platelet pool which was transfused in the patient. Sequence analysis indicates viruses in the donor and recipient samples are likely to be linked and therefore this TTI is confirmed. The associated red cell pack was transfused to an immunocompetent individual who did not require any further follow-up.

**Viral Case 12: Hepatitis E**

<b>Infection</b>	Hepatitis E virus (HEV)
<b>Year of transfusion</b>	2015
<b>SHOT report year</b>	SHOT Report 2017
<b>Component</b>	FFP
<b>No. recipients</b>	1 (+red cell recipient- see above)
<b>Morbidity</b>	Major morbidity
<b>Source</b>	Repeat male donor > 30 years
<b>Possible risk factor</b>	Donors were asymptomatic- no illness before or after donation.
<b>Reason TTI occurred</b>	HEV screening not required. No clinical illness in donor. Therefore nothing to suggest components from donation should not have been issued.
<b>Index case</b>	A male patient in his 60's received multiple plasma exchanges with FFP as treatment for Focal Segmental Glomerulosclerosis (FSGS) which he developed after undergoing a renal transplant in November 2014.
<b>Diagnosis</b>	In March 2017 following further investigations after the patient developed ascites over 6 months and portal hypertension, the patient was found to be HEV RNA positive. Public Health England confirmed these results as HEV IgM positive and IgG positive, genotype 3 with a viral load of 1,500,000 IU/mL. The patient had therefore developed chronic HEV infection, dating from at least August 2015, on a background of immunosuppression following a renal transplant. The patient subsequently developed multi-organ failure and died.
<b>Investigation</b>	Archive samples were retrieved and tested, 57 were HEV RNA negative, one sample was insufficient for testing and one was identified as HEV RNA positive, IgM and IgG negative, indicating early HEV infection in the donor at the time of donation. An associated red cell pack from the same donation did not result in transmission probably due to low levels of virus in the pack. Sequence analysis indicates viruses in the donor and recipient samples (genotype 3c) are likely to be linked and therefore this is confirmed as a TTI.

**Viral Case 13: Hepatitis A**

<b>Infection</b>	Hepatitis A virus (HAV)
<b>Year of transfusion</b>	2017
<b>SHOT report year</b>	SHOT Report 2017
<b>Component</b>	Platelets-apheresis
<b>No. recipients</b>	1
<b>Morbidity</b>	Major morbidity
<b>Source</b>	Repeat male donor > 50 years
<b>Possible risk factor</b>	Donor felt unwell two days prior to donation but recovered and attended donation, the following day the donor felt unwell and developed dark urine but no jaundice. A week after donation the donor was admitted to hospital. Upon investigation, it was found that the donor had visited a bakery that was linked in a Hepatitis A outbreak.
<b>Reason TTI occurred</b>	Donations are not routinely screened for hepatitis A.
<b>Index case</b>	A female patient in her 50's with renal cancer, neutropenic sepsis and low platelet count received an apheresis platelet unit.
<b>Diagnosis</b>	HAV RNA was detected in the recipient, however the patient had evidence of previous hepatitis A infection or immunisation (HAV IgG detected and HAV IgM negative. Sadly the patient died of their underlying disease.
<b>Investigation</b>	Health Protection Scotland and SNBTS worked together to ensure that no other donors potentially affected by the outbreak were eligible to donate for 6 months. The Public Health services in England and Scotland have modified their hepatitis A questionnaire for patients and contacts to ask an additional question about recent blood donation. Public health teams will notify their blood service if patients answer yes to this question to allow appropriate actions to be taken. Sequence analysis indicates viruses in the donor and recipient samples are likely to be linked and therefore this TTI is confirmed.

**Transfusion-Transmitted Infections (TTI) - Previous Recommendations**

<b>Year first made</b>	<b>Action</b>	<b>Recommendation</b>
<b>2013</b>	<b>Hospital Transfusion Teams (HTT), Trust/Health Board Chief Executive Officers and Medical Directors responsible for all clinical staff</b>	Clinical staff requesting investigation of a possible transfusion-transmitted infection (TTI) by the UK Blood Services are reminded to report as soon as practical to Serious Adverse Blood Reactions and Events (SABRE) and SHOT. The reporter should remember to tick the SHOT box to prompt SHOT reporting. Reporters should update their report once the outcome of the UK Blood Services investigation is known. These should be reported even if not currently screened for by the Blood Service
<b>2012</b>	<b>Clinicians, Transfusion and Microbiology Laboratory Managers</b>	Retain suspected bacterially contaminated packs, even if near empty, for return to the Blood Service as the residue can be washed out and cultured. Report a suspected bacterial TTI promptly to the Blood Service to allow recall of any associated packs for testing. If sampling packs locally for bacterial testing, use ports rather than breaching the pack to minimise environmental contamination of the pack
<b>2012</b>	<b>Clinicians, Transfusion Laboratory Managers, Hospital Transfusion Team (HTT)</b>	Hospitals and Blood Centres investigating a possible viral TTI are reminded of the importance of locating any archived recipient samples (transfusion-related or not) for testing. It is important that laboratories facilitate access to those samples (with due consent of appropriate parties including the patient)
<b>2012</b>	<b>HTTs, Clinicians</b>	Even if TTI is excluded in a case of ATR, the case should still be reported to SHOT as an ATR if necessary
<b>2012</b>	<b>Clinicians, UK Blood Services</b>	Clinicians investigating suspected viral TTIs should explore all possible risk exposures in parallel with the Blood Service investigations, in order to determine the patient's most likely source of infection. This includes checking records and testing samples taken prior to the implicated transfusion(s) to check that the recipient was not infected prior to transfusion
<b>2010</b>	<b>Hospital microbiology laboratories</b>	Attention should be paid to the sampling and storage of implicated units or their residues to avoid sampling or environmental contamination of the pack

2010	HTTs, clinicians	Even if TTI is excluded in a case of ATR, the case should still be reported to SHOT as an ATR
2010	Clinicians, UK Blood Services	Clinicians investigating suspected viral TTIs should explore all possible risk exposures in parallel with the Blood Service investigations, in order to determine the patient's most likely source of infection. This includes checking records and testing samples taken prior to the implicated transfusion(s) to check that the recipient was not infected prior to transfusion.
2009	HTTs	Staff should maintain a high index of suspicion for bacterial causes when managing acute transfusion reactions. Symptoms may appear to be related to the patient's underlying condition, and temperature rises may be small or absent altogether. A BSH guideline on the management of acute transfusion reactions has been prepared.
2009	HTTs, UK Blood Services	Processing and issues teams at the UK blood services and hospital transfusion teams should be vigilant to any abnormalities or clumps present in packs prior to transfusion, as highlighted by the Near Miss case in 2009.
2009	HTTs, UK blood services	Cleaning protocols for cold rooms and processing and storage areas should be reviewed regularly. Compliance with these should be audited.
2009	Clinicians, UK Blood Services	Clinicians investigating suspected viral TTIs should explore all possible risk exposures in parallel with the blood service investigations, in order to determine the patient's most likely source of infection.
2008	Hospital transfusion teams	Staff must maintain a high index of suspicion of bacterial causes when managing acute transfusion reactions. Symptoms may appear to be allergic in nature, but cultures must still be performed whenever bacterial contamination is a possibility.
2005, 2008, 2009	Hospital transfusion teams, UK blood services	Where bacterial contamination is suspected, staff should report the incident to the blood services as soon as possible in order to facilitate the return of implicated packs and the recall of any associated units. Attention should be paid to the sampling and storage of implicated units or their residues to avoid environmental contamination of the pack.
2003, 2008	UK blood services, SaBTO, blood collection teams, hospital transfusion laboratories, staff undertaking pre-transfusion bedside	Strategies to reduce bacterial contamination of blood components should continually be reviewed. These include: <ul style="list-style-type: none"> <li>- Diversion of the first 20–30 mL of the donation (likely to contain any organisms entering the collection needle from the venepuncture site)</li> <li>- Enhanced donor arm cleansing using chlorhexidene</li> <li>- Consideration of bacterial screening interventions and/or pathogen inactivation</li> </ul>

	<b>checking</b>	- Adherence to BSH guidelines (2009) with regard to the visual inspection of blood components for any irregular appearance immediately prior to transfusion
--	-----------------	---